Closed-System CAR T Cell Manufacturing Without Depletion Steps
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing manufacturing processes for chimeric antigen receptor (CAR) T cells are vulnerable to contamination and reduce cellular function, leading to increased toxicity and reduced yield, necessitating the development of safer and more efficient methods.
Innovation Solution
A closed system method for manufacturing CAR T cells that omits CD14+/CD25+ depletion and transducing enhancers, using CD62L+ enrichment and transducing in the absence of polybrene, protamine sulfate, LentiBoost™, or Vectofusin-1, and expanding cells with IL-2 and IL-15, followed by cryopreservation in specific media.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If open manufacturing steps including centrifugation are used, then manufacturing process is simple, but contamination risk increases and cellular function is reduced
Solution Approach 1:
The patent implements a closed system manufacturing process that operates in a controlled, sterile environment to replace open manufacturing steps. This eliminates exposure to contaminants while maintaining ease of manufacture through standardized closed-system protocols and pre-prepared reagents, directly resolving the contradiction between process simplicity and contamination risk.
2Ease of manufacture
If open manufacturing steps including centrifugation are used, then manufacturing process is simple, but cellular function is reduced
Solution Approach 1:
The closed system manufacturing process protects T cells from mechanical stress and environmental damage associated with open centrifugation steps. By maintaining cells in a controlled environment throughout the manufacturing process, cellular function and viability are preserved while keeping the process equally simple through standardized protocols.
3Productivity
If transducing enhancers are used, then transduction efficiency is improved, but cellular function is reduced leading to increased toxicity
Solution Approach 1:
The patent removes transducing enhancers (polybrene, protamine sulfate, LentiBoost, Vectofusin-1) from the manufacturing process entirely. This extraction of harmful substances eliminates the source of increased cytokine release syndrome while maintaining transduction efficiency through optimized viral vector design and controlled transduction conditions in the closed system.
4Ease of manufacture
If CD14+/CD25+ depletion is performed, then manufacturing process follows conventional protocol, but cellular function is reduced
Solution Approach 1:
The patent eliminates the CD14+/CD25+ depletion step from the manufacturing process. This removal of the conventional depletion protocol prevents the associated reduction in cellular function and cytokine release while maintaining ease of manufacture through streamlined processing in the closed system, directly resolving the contradiction between protocol adherence and cellular function preservation.
Data Source
AI summary
The present disclosure relates to methods of manufacturing Chimeric Antigen Receptor (CAR) T cells. Notably, the manufacturing method omits the CD14+/CD25+ depletion step. Additionally, by starting with CD62L enrichment of naïve and memory T cells, the resulting CAT T cells show reduced release of proinflammatory cytokines. Furthermore, the transduced cells show improved quiescence after removal of the transactivation agent.